Semler Scientific Inc - SMLR STOCK NEWS

Semler Scientific (Nasdaq: SMLR) reported a 37% increase in annual revenues to $53.0 million for 2021, compared to $38.6 million in 2020. Net income rose by 23% to $17.2 million, translating to $2.56 per basic share. However, Q4 revenue dipped 4% year-over-year to $11.5 million, with net income dropping 72% to $1.5 million. Notably, the cost of revenues surged 120% in Q4, reflecting a $1.2 million inventory write-down. Despite these challenges, the company maintains a optimistic outlook for continued profitability and growth.

Semler Scientific (Nasdaq: SMLR) will report its fourth quarter and full year financial results for 2021 on February 28, 2022, after U.S. market close. A conference call hosted by CEO Doug Murphy-Chutorian will occur at 4:30 PM ET the same day, featuring senior executives Andrew Weinstein and Dennis Rosenberg. Participants can pre-register for the call to receive a passcode for immediate access. Semler Scientific specializes in technology solutions for healthcare and offers the FDA-cleared QuantaFlo®, a test to evaluate risks of chronic diseases.

Semler Scientific (SMLR) reported strong financial results for Q3 and nine months ending September 30, 2021. Revenues reached $14.0 million, a 30% increase year-over-year, with a pre-tax net income of $5.3 million, down 6% compared to last year. For the nine months, revenues surged 56% to $41.5 million, with total net income rising 82% to $15.7 million. Despite a sequential decline in fee-per-test revenue attributed to the Delta variant, the company remains profitable and expects ongoing revenue growth. Cash reserves improved to $35.9 million.

Semler Scientific, Inc. (Nasdaq: SMLR) announced it will release its financial results for Q3 and the first nine months of 2021 after U.S. markets close on November 1, 2021. CEO Doug Murphy-Chutorian will host a conference call at 4:30 PM ET, joined by senior finance and marketing executives. Participants can pre-register for the call and access it via phone if unable to register online. Semler specializes in technology solutions for healthcare providers, notably with its FDA-cleared QuantaFlo® product for diagnosing peripheral arterial disease.

Semler Scientific, Inc. (SMLR) announced CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg's participation in several virtual investor conferences in September 2021. The events include the Colliers 2021 Institutional Investor Conference on September 9, H.C. Wainwright & Co. 23rd Annual Global Investment Conference on September 13, and the 2021 Best Ideas Growth (BIG5) Conference on September 14-15. Semler provides technology solutions to enhance healthcare provider effectiveness and offers the QuantaFlo® test for diagnosing peripheral arterial disease.

Semler Scientific (OTCQB: SMLR) reported a significant financial uplift for Q2 and H1 2021. Revenues surged to $14.3 million, marking a 125% increase from $6.4 million year-over-year. Net income also rose sharply by 522% to $6.7 million, with earnings per share reaching $1.00. The company holds $28.5 million in cash and aims for continued profitability and growth in the expanding peripheral arterial disease (PAD) testing market.

Semler Scientific, Inc. (SMLR) announced it will report its financial results for the second quarter and first half of 2021 on August 2, 2021, after U.S. markets close. The conference call will be hosted by CEO Doug Murphy-Chutorian at 4:30 PM ET, alongside senior finance and marketing executives. Semler focuses on technology solutions to enhance healthcare efficiency, having launched QuantaFlo®, a point-of-care test for diagnosing peripheral arterial disease. This test helps evaluate patient risk for heart attacks and strokes, aligning with Semler's mission to support better patient care.

Semler Scientific, Inc. (OTCQB: SMLR), based in Santa Clara, California, announced that CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present an overview at the Raymond James Human Health Innovation Conference on June 22, 2021, at 12:00 pm ET. A live webcast of the presentation will be available on the company's website under "Events and Presentations". Semler focuses on technology solutions that enhance healthcare efficiency, including its FDA-cleared product, QuantaFlo®, designed for diagnosing peripheral arterial disease.

Semler Scientific (SMLR) reported a strong Q1 2021 with revenues of $13.2 million, up 40% from Q1 2020's $9.4 million. The company achieved a 74% increase in pre-tax net income to $6.0 million, translating to $0.73 per basic share. Cash reserves rose to $26.5 million, marking a substantial $15.3 million increase. Future growth is anticipated as Semler enters a distribution agreement worth $2.0 million for product inventory. The company aims to outpace expense growth while maintaining profitability.